Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

242 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
High efficacy with five days schedule of oral fludarabine phosphate and cyclophosphamide in patients with previously untreated chronic lymphocytic leukaemia.
Cazin B, Divine M, Leprêtre S, Travade P, Tournilhac O, Delmer A, Jaubert J, Feugier P, Dreyfus B, Mahé B, Grosbois B, Maloisel F, Eghbali H, Dumontet C, Bénichou J, Guibon O, Leleu X, Leporrier M, Maloum K. Cazin B, et al. Among authors: delmer a. Br J Haematol. 2008 Oct;143(1):54-9. doi: 10.1111/j.1365-2141.2008.07309.x. Epub 2008 Aug 15. Br J Haematol. 2008. PMID: 18710390 Free article. Clinical Trial.
Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia.
Tournilhac O, Cazin B, Leprètre S, Diviné M, Maloum K, Delmer A, Grosbois B, Feugier P, Maloisel F, Villard F, Villemagne B, Bastit D, Belhadj K, Azar N, Michallet M, Manhès G, Travade P. Tournilhac O, et al. Among authors: delmer a. Blood. 2004 Jan 1;103(1):363-5. doi: 10.1182/blood-2003-05-1449. Epub 2003 Sep 11. Blood. 2004. PMID: 12969985 Free article.
Quantitative analysis of nucleoside transporter and metabolism gene expression in chronic lymphocytic leukemia (CLL): identification of fludarabine-sensitive and -insensitive populations.
Mackey JR, Galmarini CM, Graham KA, Joy AA, Delmer A, Dabbagh L, Glubrecht D, Jewell LD, Lai R, Lang T, Hanson J, Young JD, Merle-Béral H, Binet JL, Cass CE, Dumontet C. Mackey JR, et al. Among authors: delmer a. Blood. 2005 Jan 15;105(2):767-74. doi: 10.1182/blood-2004-03-1046. Epub 2004 Sep 28. Blood. 2005. PMID: 15454483 Free article. Clinical Trial.
Concomitant Epstein-Barr virus-negative large B-cell lymphoma (Richter syndrome) and Epstein-Barr virus- positive B-cell lymphoproliferation after treatment with fludarabine and cyclophosphamide in a patient with B-cell chronic lymphocytic leukemia.
Compérat E, Delmer A, Le Tourneau A, Molina TJ, Diebold J, Audouin J. Compérat E, et al. Among authors: delmer a. Arch Pathol Lab Med. 2006 Aug;130(8):1227-30. doi: 10.5858/2006-130-1227-CEVLBL. Arch Pathol Lab Med. 2006. PMID: 16879030 Free article.
IGHV gene mutational status and LPL/ADAM29 gene expression as clinical outcome predictors in CLL patients in remission following treatment with oral fludarabine plus cyclophosphamide.
Maloum K, Settegrana C, Chapiro E, Cazin B, Leprêtre S, Delmer A, Leporrier M, Dreyfus B, Tournilhac O, Mahe B, Nguyen-Khac F, Lesty C, Davi F, Merle-Béral H. Maloum K, et al. Among authors: delmer a. Ann Hematol. 2009 Dec;88(12):1215-21. doi: 10.1007/s00277-009-0742-6. Epub 2009 Apr 2. Ann Hematol. 2009. PMID: 19340428
Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.
Preudhomme C, Guilhot J, Nicolini FE, Guerci-Bresler A, Rigal-Huguet F, Maloisel F, Coiteux V, Gardembas M, Berthou C, Vekhoff A, Rea D, Jourdan E, Allard C, Delmer A, Rousselot P, Legros L, Berger M, Corm S, Etienne G, Roche-Lestienne C, Eclache V, Mahon FX, Guilhot F; SPIRIT Investigators; France Intergroupe des Leucémies Myéloïdes Chroniques (Fi-LMC). Preudhomme C, et al. Among authors: delmer a. N Engl J Med. 2010 Dec 23;363(26):2511-21. doi: 10.1056/NEJMoa1004095. N Engl J Med. 2010. PMID: 21175313 Free article. Clinical Trial.
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.
Salles G, Seymour JF, Offner F, López-Guillermo A, Belada D, Xerri L, Feugier P, Bouabdallah R, Catalano JV, Brice P, Caballero D, Haioun C, Pedersen LM, Delmer A, Simpson D, Leppa S, Soubeyran P, Hagenbeek A, Casasnovas O, Intragumtornchai T, Fermé C, da Silva MG, Sebban C, Lister A, Estell JA, Milone G, Sonet A, Mendila M, Coiffier B, Tilly H. Salles G, et al. Among authors: delmer a. Lancet. 2011 Jan 1;377(9759):42-51. doi: 10.1016/S0140-6736(10)62175-7. Epub 2010 Dec 20. Lancet. 2011. PMID: 21176949 Clinical Trial.
Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial.
Lepretre S, Aurran T, Mahé B, Cazin B, Tournilhac O, Maisonneuve H, Casasnovas O, Delmer A, Leblond V, Royer B, Corront B, Chevret S, Delépine R, Vaudaux S, Van Den Neste E, Béné MC, Letestu R, Cymbalista F, Feugier P. Lepretre S, et al. Among authors: delmer a. Blood. 2012 May 31;119(22):5104-10. doi: 10.1182/blood-2011-07-365437. Epub 2012 Feb 14. Blood. 2012. PMID: 22337714 Free article. Clinical Trial.
Rituximab therapy for hairy cell leukemia: a retrospective study of 41 cases.
Leclerc M, Suarez F, Noël MP, Vekhoff A, Troussard X, Claisse JF, Thieblemont C, Maloisel F, Beguin Y, Tamburini J, Barbe C, Delmer A. Leclerc M, et al. Among authors: delmer a. Ann Hematol. 2015 Jan;94(1):89-95. doi: 10.1007/s00277-014-2175-0. Epub 2014 Sep 7. Ann Hematol. 2015. PMID: 25195120 Free article.
242 results